The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 31, 2022
Filed:
Jul. 08, 2019
Applicant:
Board of Regents, the University of Texas System, Austin, TX (US);
Inventors:
Laurence J. Neil Cooper, Houston, TX (US);
Hiroki Torikai, Houston, TX (US);
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61K 39/00 (2006.01); C12N 5/0783 (2010.01); A61P 37/02 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 39/0011 (2013.01); A61K 39/00111 (2018.08); A61K 39/00117 (2018.08); A61K 39/00119 (2018.08); A61K 39/001104 (2018.08); A61K 39/001106 (2018.08); A61K 39/001109 (2018.08); A61K 39/001112 (2018.08); A61K 39/001117 (2018.08); A61K 39/001119 (2018.08); A61K 39/001124 (2018.08); A61K 39/001129 (2018.08); A61K 39/001151 (2018.08); A61K 39/001164 (2018.08); A61K 39/001171 (2018.08); A61K 39/001174 (2018.08); A61K 39/001181 (2018.08); A61K 39/001182 (2018.08); A61P 37/02 (2018.01); C12N 5/0636 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C12N 2510/00 (2013.01); Y02A 50/30 (2018.01);
Abstract
The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising disrupted T cell receptor and/or HLA and comprising a chimeric antigen receptor. In certain embodiments, the compositions are employed allogeneically as universal reagents for 'off-the-shelf' treatment of medical conditions such as cancer, autoimmunity, and infection. In particular embodiments, the T cell receptor-negative and/or HLA-negative T cells are generated using zinc finger nucleases, for example.